Key result
Adding sotatercept to treprostinil triggers reversible high-output heart failure in pulmonary arterial hypertension.
Why the study?
High-output heart failure secondary to prostacyclin analogue toxicity following sotatercept initiation in pulmonary arterial hypertension is a rare and poorly characterized complication.
Case Report (n=1)
High-output heart failure may occur with prostacyclin toxicity after sotatercept initiation in complex patients with pulmonary arterial hypertension, underscoring the need for careful hemodynamic assessment.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for high-output HF when adding sotatercept to prostacyclin in PAH; leaves open interaction risks for prospective study.
BACKGROUND: We present a rare case of high-output heart failure (HF) resulting from prostacyclin analogue toxicity following the addition of sotatercept. CASE SUMMARY: A 36-year-old woman with World Health Organization Group I pulmonary arterial hypertension (PAH), a history of suspected but hemodynamically unconfirmed heart failure with preserved ejection fraction and morbid obesity maintained on treprostinil and sildenafil therapy, developed progressive hypoxia, anasarca and dyspnea 3 months after sotatercept initiation. Serial right heart catheterizations demonstrated a shift from severe precapillary pulmonary hypertension to a high-output state with elevated biventricular filling pressures. The patient required intensive care unit admission for diuresis, vasopressors and continuous renal replacement therapy. Treprostinil discontinuation improved hemodynamics, followed by normalization after sotatercept discontinuation. DISCUSSION: Severe obesity in association with synergistic vasodilatory effects from sotatercept and treprostinil therapy reduced systemic vascular resistance, increased cardiac output and raised biventricular filling pressures, culminating in high-output HF and unmasking occult diastolic dysfunction. TAKE-HOME MESSAGE: High-output HF may occur with prostacyclin toxicity after sotatercept initiation, underscoring individualized careful hemodynamic assessment in complex patients with pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Medina-Hernandez et al. (2026) conducted a case report in Pulmonary arterial hypertension (n=1). Sotatercept was evaluated on High-output heart failure. Addition of sotatercept to treprostinil therapy in a patient with pulmonary arterial hypertension resulted in high-output heart failure, which resolved upon discontinuation of both agents.
Synapse has enriched 10 related papers. Consider them for comparative context: